ATAGI 关于 5 至 11 岁儿童接种辉瑞 COVID-19 儿科疫苗加强剂量的建议
ATAGI have recommended COVID-19 booster doses for some groups of 5-11 year olds who have previously completed a primary course of COVID-19 vaccination. Eligible groups include those with severe immunocompromise, a disability with significant or complex health needs, or those with complex/multiple health conditions that increase the risk of severe COVID-19 disease.
Boosters in this age group can be administered 3 or more months after completing a primary course of COVID-19 vaccines. An interval of 3 months between COVID-19 infection and COVID vaccines is recommended.
There is currently not enough evidence to support booster doses for other groups of 5-11 year olds, however recommendations may change as more evidence emerges. All children in this age group are recommended to receive a primary course of COVID-19 vaccination.
To read the recommendations in full please follow the link below.
AusVaxSafety 提供世界首个 JYNNEOS 猴痘疫苗的实时安全数据
新发布的 AusVaxSafety 对 1,300 多剂 JYNNEOS® 首剂疫苗的监测数据显示，54% 疫苗接种者在疫苗接种后的前 7 天内没有出现任何副作用。在报告症状的疫苗接种者中，副作用通常是轻微且短暂的，包括局部反应、疲劳、头痛和肌肉/关节疼痛。
为了提供有关在澳大利亚使用 JYNNEOS® 的进一步指导，AusVaxSafety 将继续收集和发布这些信息，包括第 2 剂后的副作用。
要阅读完整更新，请单击下面的链接。
全球首个 JYNNEOS 猴痘疫苗的实时安全数据可从 AusVax安全
ATAGI 关于 12-17 岁青少年使用 Novavax 疫苗的建议
ATAGI have now recommended that adolescents aged 12-17 years can receive the Novavax COVID-19 vaccine for their primary course of COVID-19 vaccination. This recommendation provides another vaccine brand option, in addition to Pfizer and Moderna, for individuals in this age group.
A Novavax primary schedule consists of 2 doses, administered 8 weeks apart. Those with 严重的免疫功能低下 should receive 3 doses.
Whilst Novavax is not currently registered for use as a booster dose in adolescents aged 12-17 years, ATAGI advises that it may be used for this purpose, when Pfizer is not suitable for that person.
To read the recommendations in full please follow the link below.
ATAGI recommendations on the use of the Novavax vaccine for adolescents aged 12-17 years.
疫苗工作 GAVI：过去和现在有关猴痘的五张图表
Despite the first cases of monkeypox infection in humans being reported in the 1970’s, previous outbreaks of disease have been relatively small compared with the international outbreak we are currently experiencing. Human to human transmission has been historically uncommon with cases limited to smaller geographical regions. Current rates of infection, with extensive human to human transmission and wide global spread has led this outbreak to be a very unique scenario.
The following article uses the latest data to explore the current rates of infection across different demographics and regions, the impact of pre-existing medical conditions, as well as vaccine access and severity of disease.
To read the article in full, click on the link below.
疫苗工作 GAVI：过去和现在有关猴痘的五张图表
To view our reference page on monkeypox, click on the link below.
MVEC：猴痘
VACSIG 网络研讨会录音现已提供
A webinar recording is now available from the recent Vaccination Special Interest Group (VACSIG) event on Wednesday 17 August. The topic for the webinar was Monkeypox & smallpox vaccines: an Australian perspective, and featured a panel of expert speakers including MVEC’s A/Prof Nigel Crawford.
To view the recording, please click on the link below.
VACSIG Webinar 17 August
ATAGI 关于 5 岁以下儿童使用 COVID-19 疫苗的建议
ATAGI have now recommended COVID-19 vaccination for some children aged 6 months – 5 years. Eligible groups include those with severe immunocompromise, a disability with severe or complex health needs, or those with multiple/complex health conditions that increase the risk of severe COVID-19 disease.
A paediatric formula of the Moderna COVID-19 vaccine has been approved by the TGA in this age group for children in the groups mentioned above. A primary two-dose schedule, 8 weeks apart is recommended, with the dose being 25mcg. Children in this age group with severe immunocompromise are recommended to complete a 3-dose primary schedule.
基于一系列因素，ATAGI 目前不建议不属于上述类别的 6 个月至 5 岁儿童接种 COVID 疫苗。
随着替代品牌或变体 COVID-19 疫苗在这个年龄段可用，或者如果出现流行病学变化（例如出现新的令人担忧的变体），建议可能会发生变化。
To read the recommendations in full please follow the link below.
ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years
COVID-19 疫苗对超过 200,000 名澳大利亚儿童的安全性：来自 AusVaxSafety 的令人放心的数据
New AusVaxSafety research which analysed 392,268 survey responses via AusVaxSafety’s national active safety surveillance system between July 2021 and May 2022, has found that Australian children aged 5-15 years report fewer side effects in the days following mRNA COVID-19 vaccination than those reported in clinical trials and published safety data.
Importantly, fever was reported low in the youngest age group, comparable to that seen following annual influenza vaccination. Additionally, there were also no self-reported cases of myocarditis and pericarditis identified in the study.
AusVaxSafety will commence surveillance in children aged 6 months to 5 years once COVID-19 vaccines become available in this age group.
To access the research in full, click on the link below.
Safety of COVID-19 vaccines in >200,000 Aussie kids: reassuring data from AusVax安全
Flinders University Alumni publication featuring A/Prof Nigel Crawford: Providing the vital boost for us to fight COVID-19
MVEC’s Associate Professor Nigel Crawford was featured in the Flinders University College of Medicine and Public Health Alumni magazine regarding his significant contribution to Australia’s COVID-19 vaccine rollout. As the current chair of the Australian Technical Advisory Group for Immunisation (ATAGI), Nigel discusses his role in steering Australia’s uptake of COVID-19 vaccines, including effective communication and the ability to remain flexible when responding to and adapting vaccine advice for the general public.
To read the full article, follow the link below.
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
ATAGI have updated their COVID-19 winter booster dose recommendations to include additional risk groups. The groups now eligible for winter booster doses include:
- Any adult aged 65 years and older
- 16 岁及以上的老年护理或残疾护理居民
- 16 岁及以上患有严重疾病的人 免疫妥协
- Aboriginal and Torres Strait Islander adults aged 50 years and older.
- Individuals from 16 years of age who have complex, chronic or severe conditions [refer to page 3 of ATAGI statement below]
COVID-19 winter booster doses are not currently recommended for other groups including healthy people aged 16 to 64 years, healthy individuals with occupational risk factors (eg. healthcare workers) or pregnant women without additional risk factors.
mRNA vaccines are the preferred option for booster doses with Comirnaty (Pfizer) available to give from 16 years of age and Spikevax (Moderna) from 18 years. In people aged 18 years or older with a contraindication to mRNA vaccines Vaxzevria (AstraZeneca) may be considered. Nuvaxovid (Novavax) can be used in individuals 18 years or older in circumstances where no other COVID-19 vaccine is suitable.
要完整阅读更新后的建议，请单击以下链接：
Expanded ATAGI recommendations on winter COVID-19 booster doses for people at increased risk of severe COVID-19
ABC：昆士兰州流感病例激增促使医生对儿童和弱势群体发出疫苗警告
专家警告说，今年儿童越来越容易感染流感病。 MVEC 的儿科传染病专家 Angela Berkhout 博士解释说，由于冠状病毒大流行，儿童，尤其是两岁以下儿童对流感的自然免疫力较低。
虽然流感季节尚未达到高峰，但昆士兰州的医院已经涌入了大量需要住院治疗的流感患者，包括重症监护。本文探讨了为儿童、65 岁以上的老年人和其他弱势群体接种疫苗的主要考虑因素。
要阅读全文，请点击以下链接：
ABC：昆士兰州流感病例激增促使医生对儿童和弱势群体发出疫苗警告
有关流感疫苗和 2022 年流感季节的更多信息，请参阅我们的以下资源：